Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
53,136,600
-
Total 13F shares
-
33,283,050
-
Share change
-
-934,165
-
Total reported value
-
$159,762,120
-
Put/Call ratio
-
6.5%
-
Price per share
-
$4.80
-
Number of holders
-
75
-
Value change
-
-$6,348,070
-
Number of buys
-
35
-
Number of sells
-
31
Institutional Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q3 2023
As of 30 Sep 2023,
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) was held by
75 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
33,283,050 shares.
The largest 10 holders included
venBio Partners LLC, FMR LLC, Vivo Capital, LLC, ORBIMED ADVISORS LLC, BlackRock Inc., Redmile Group, LLC, BRAIDWELL LP, VANGUARD GROUP INC, Logos Global Management LP, and Cormorant Asset Management, LP.
This page lists
75
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.